Aimeison Resubmits Hong Kong IPO After 10 Years Without Profit
Second Hong Kong IPO Attempt After Prior Filing Lapse
Wuhan Aimeison Life Sciences Co., Ltd., a Chinese early cancer screening company, has resubmitted its prospectus to the Hong Kong Stock Exchange for main board listing, with China Bohai Bank
CryptoFrontier·04-22 04:12















